Bharat Biotech's COVID-19 vaccine 'COVAXIN' has demonstrated an interim efficacy of 81 per cent in its Phase 3 clinical trial, the manufacturer said on Wednesday.
According to the company, the trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR.
(THE NEW INDIAN EXPRESS)